γδ T cell activation may contribute to antitumor immunity stimulated by intralesional BCG immune therapy for cutaneous melanoma metastases
نویسندگان
چکیده
In-transit melanoma metastasis can lead to significant locoregional toxicity, due to painful, bleeding, or necrotic lesions, which may become superinfected. Intralesional immunotherapy is a rational approach to such disease as the lesions are accessible and provide a source of ideally matched tumor antigen to facilitate local, and possibly systemic, immune responses. Mycobacterium bovis Bacille Calmette-Guerin (BCG) is one of several local therapy options recommended in the NCCN Guidelines, version 3.2015 for stage III melanoma. Direct injection of BCG into metastatic melanoma lesions in the skin (intralesional BCG or ILBCG) resulted in 90% regression of injected lesions and 17% regression of uninjected lesions in immunocompetent patients. Although the mechanism through which BCG functions to eliminate tumor is unclear, it is likely immune mediated and involves T cells. BCG and other mycobacteria have a propensity to stimulate T cells expressing Vg9Vδ2 T cell receptors, thus, we hypothesized that gδ T cells contribute to BCG-mediated antitumor immunity in in-transit melanoma. We detected an increase in Vg9 T cell infiltration in uninjected ILBCG lesion of one patient during the course of ILBCG therapy as well as increased gene expression of BTN3A1 (butyrophilin), a protein that facilitates gδ T cell activation, suggesting the prevalence and migration of gδ T cells into skin lesions. We further found that butyrophilin, and gδ TCR expression were upregulated in BCG-stimulated PBMC of melanoma patients (n=5). BCG also induced proliferation and activation of gδ T cells as evidenced by a 2,000-fold increase in Vg9 T cell proliferation and a 9and 19-fold increase in CD69 and HLA-DR expression in Vg9 T cells, respectively. Moreover, BCG stimulated a 5 to 21-fold increase in IFN-g producing gδ T cells in comparison to unstimulated PBMC (n=3), whereas 0 to 2.2-fold increases in IFN-g producing ab T cells were detected in response to BCG. Vg9 T cells expanded with BCG made more granzyme A (p < 0.04) and granzyme B (p < 0.0008) compared to unstimulated PBMC. Finally, an in-transit melanoma tumor that was regressing after ILBCG yielded a 117-fold increase of gδ T cells producing IFNg relative to a non-regressing tumor from the same patient. These data suggest that immune therapy approaches that promote tumor recognition by gδ T cells and boost effector functions are feasible and that further studies should be performed to define the role of gδ T cells BCG-mediated regression for in-transit melanoma patients.
منابع مشابه
Mycobacterium bovis Bacillus Calmette–Guérin Alters Melanoma Microenvironment Favoring Antitumor T Cell Responses and Improving M2 Macrophage Function
Intralesional Mycobacterium bovis bacillus Calmette-Guérin (BCG) has long been a relatively inexpensive therapy for inoperable cutaneous metastatic melanoma (CMM), although intralesional BCG skin mechanisms remain understudied. We analyzed intralesional BCG-treated CMM lesions combined with in vitro studies to further investigate BCG-altered pathways. Since macrophages play a pivotal role again...
متن کاملInsights into Local Tumor Microenvironment Immune Factors Associated with Regression of Cutaneous Melanoma Metastases by Mycobacterium bovis Bacille Calmette–Guérin
Mycobacterium bovis bacille Calmette-Guérin (BCG) is listed as an intralesional (IL) therapeutic option for inoperable stage III in-transit melanoma in the National Comprehensive Cancer Network Guidelines. Although the mechanism is unknown, others have reported up to 50% regression of injected lesions, and 17% regression of uninjected lesions in immunocompetent patients after direct injection o...
متن کاملAutoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette–Guérin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced melanoma. The first ICI to demonstrate clinical benefit, ipilimumab, targets cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4); however, the long-term overall survival is just 22%. More than 40 years ago intralesional (IL) bacillus Calmette-Guérin (BCG), a living attenuated strain of Mycobacterium bovis, was fo...
متن کاملIL-36γ Transforms the Tumor Microenvironment and Promotes Type 1 Lymphocyte-Mediated Antitumor Immune Responses.
Cytokines play a pivotal role in regulating tumor immunogenicity and antitumor immunity. IL-36γ is important for the IL-23/IL-17-dominated inflammation and anti-BCG Th1 immune responses. However, the impact of IL-36γ on tumor immunity is unknown. Here we found that IL-36γ stimulated CD8(+) T cells, NK cells, and γδ T cells synergistically with TCR signaling and/or IL-12. Importantly, IL-36γ exe...
متن کاملIntralesional Injection of Rose Bengal Induces a Systemic Tumor-Specific Immune Response in Murine Models of Melanoma and Breast Cancer
Intralesional (IL) injection of PV-10 has shown to induce regression of both injected and non-injected lesions in patients with melanoma. To determine an underlying immune mechanism, the murine B16 melanoma model and the MT-901 breast cancer model were utilized. In BALB/c mice bearing MT-901 breast cancer, injection of PV-10 led to regression of injected and untreated contralateral subcutaneous...
متن کامل